Scarica l'app Stockscreener
44.23
1.80%
-0.765
Precedente Chiudi:
$45.00
Aprire:
$44.64
Volume 24 ore:
2.48M
Relative Volume:
0.72
Capitalizzazione di mercato:
$4.82B
Reddito:
-
Utile/perdita netta:
$-95.90M
Rapporto P/E:
-33.51
EPS:
-1.32
Flusso di cassa netto:
$-79.09M
1 W Prestazione:
+9.84%
1M Prestazione:
+95.88%
6M Prestazione:
+1,039%
1 anno Prestazione:
+556.61%
Intervallo 1D:
$43.55
$45.09
Intervallo di 1 settimana:
$40.00
$48.26
Portata 52W:
$1.865
$48.26
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Nome
Terns Pharmaceuticals Inc
Settore
Industria
Telefono
650-525-5535 EXT.101
Indirizzo
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Confronta TERN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
44.28 | 4.89B | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.50 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.88 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.59 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.05 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.50 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-11-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-04 | Ripresa | H.C. Wainwright | Neutral |
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2024-10-31 | Iniziato | Oppenheimer | Outperform |
| 2023-06-22 | Iniziato | Mizuho | Buy |
| 2023-06-07 | Iniziato | Jefferies | Buy |
| 2023-05-31 | Iniziato | ROTH MKM | Buy |
| 2023-05-08 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-14 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-02-07 | Iniziato | UBS | Buy |
| 2022-09-12 | Iniziato | H.C. Wainwright | Neutral |
| 2021-09-14 | Ripresa | Goldman | Buy |
| 2021-03-02 | Iniziato | Cowen | Outperform |
| 2021-03-02 | Iniziato | Goldman | Buy |
| 2021-03-02 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Terns Pharmaceuticals Inc Borsa (TERN) Ultime notizie
Biotech ETF SBIO Hovers Near Peak on Rally - ETF Database
Terns Pharmaceuticals raises $747.5 million in upsized offering - Traders Union
Terns Pharmaceuticals (TERN) climbs 53% on stellar leukemia treatment trial - MSN
Terns Pharmaceuticals (TERN) Climbs 53% on Stellar Leukemia Treatment Trial - Insider Monkey
Pharmaceutical Stocks To Follow TodayDecember 10th - MarketBeat
10 Stocks Delivering Explosive 18-190% Gains - Insider Monkey
symbol__ Stock Quote Price and Forecast - CNN
Terns Pharmaceutical prices stock at $40 per share - MSN
Terns Pharmaceuticals raises $747.5 million in public offering - Investing.com
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Citizens Analyst Raises Price Target for Terns Pharma (TERN) to $57.00 | TERN Stock News - GuruFocus
Terns Pharmaceuticals, Inc. Announces Upsized Public Offering - TradingView — Track All Markets
Terns Pharmaceuticals stock price target raised to $57 from $35 at Citizens - Investing.com Canada
Terns Pharmaceuticals Stock Surge: Analyzing the Leap - StocksToTrade
Jefferies raises Terns Pharmaceuticals stock price target to $70 on CML data - Investing.com Canada
Terns Pharmaceuticals Stock Soars After Leukemia Drug Delivers Big Early Responses In Tough-To-Treat Patients - Stocktwits
Terns Pharmaceuticals Stock Soars Amid Promising Drug Trial - TipRanks
TERN Upsizes Stock Offering to $502M - GuruFocus
Terns Pharmaceuticals (TERN) Announces Upsized Public Offering - GuruFocus
Why Terns Pharmaceuticals (TERN) Is Up 54.9% After Upsized $650 Million Equity Raise Following TERN-701 Data - Yahoo Finance
Terns Pharmaceuticals proposes $400M equity offering - MSN
Terns Pharmaceuticals Prices Upsized $650 Million Common Stock Offering - marketscreener.com
Terns Pharmaceuticals prices upsized $650 million public offering By Investing.com - Investing.com Nigeria
Terns Pharmaceuticals (TERN): Reassessing Valuation After CARDINAL CML Data Fuels Sharp Share Price Surge - Yahoo Finance
Terns Pharmaceuticals prices upsized $650 million public offering - Investing.com
Terns announces pricing of upsized $650 million public offering at $40 per share - marketscreener.com
Terns Announces Pricing of Upsized $650 Million Public Offering | Associated Press | syndication news - Enidnews.com
Terns Announces Pricing of Upsized $650 Million Public Offering - Yahoo Finance
Terns Pharmaceuticals Stock Skyrockets: Should You Dive In? - StocksToTrade
BMO Capital Maintains Terns Pharmaceuticals (TERN) Outperform Recommendation - Nasdaq
Terns (TERN) hits all-time high on stellar leukemia treatment results - MSN
Terns (TERN) Hits All-Time High on Stellar Leukemia Treatment Results - Finviz
Terns Pharmaceuticals: CML Data Blows Wall Street AwayAgain (NASDAQ:TERN) - Seeking Alpha
Oppenheimer Raises TERN Price Target by 107% to $58 | TERN Stock News - GuruFocus
Terns Pharma (TERN) Analyst Rating Update: Price Target Raised b - GuruFocus
Barclays Raises Terns Pharma (TERN) Price Target to $56 | TERN Stock News - GuruFocus
Terns Pharmaceuticals price target raised to $56 from $35 at Truist - TipRanks
Terns Pharmaceuticals stock rating reiterated by BMO Capital with $54 target - Investing.com South Africa
Terns Pharmaceuticals (TERN) Announces $400M Public Offering Pla - GuruFocus
Mizuho Raises Terns Pharma (TERN) Price Target to $54, Maintains Outperform Rating | TERN Stock News - GuruFocus
Oppenheimer Adjusts PT on Terns Pharmaceuticals to $58 From $28, Maintains Outperform Rating - marketscreener.com
Broadcom To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Terns Pharmaceuticals price target raised to $58 from $28 at Oppenheimer - TipRanks
Terns Pharmaceuticals (TERN) Launches $400M Public Offering - GuruFocus
Terns Pharmaceuticals price target raised to $54 from $33 at Mizuho - TipRanks
Truist Raises Price Target on Terns Pharmaceuticals to $56 From $35, Keeps Buy Rating - marketscreener.com
Mizuho Raises Price Target on Terns Pharmaceuticals to $54 From $33, Keeps Outperform Rating - marketscreener.com
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster - Benzinga
Terns Pharmaceuticals launches $400 million public offering By Investing.com - Investing.com Nigeria
H.C. Wainwright raises Terns Pharmaceuticals stock price target to $60 on CML drug data - Investing.com UK
Mizuho raises Terns Pharmaceuticals stock price target to $54 on CML drug data - Investing.com
Terns Pharmaceuticals Inc Azioni (TERN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.56%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):